Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun;75(6):e14011.
doi: 10.1111/ijcp.14011. Epub 2021 Jan 25.

A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia

Qin Yang  1 , Xin Wang  1
Affiliations
Case Reports

A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia

Qin Yang et al. Int J Clin Pract. 2021 Jun.

Abstract

Case presentation: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.

Discussion: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.

Conclusion: Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The relative serum levels of CK and MPO of patients. Normal levels of CK and MPO: CK: 55‐170 U/L, MPO: 0‐110 ng/mL
FIGURE 2
FIGURE 2
Changes in serum hemoglobin with time and the treatment plan. Normal levels of hemoglobin (HGB): HGB: 13.0‐17.5 g/dL
See this image and copyright information in PMC

References

    1. GBD Chronic Kidney Disease Collaboration . Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709‐733. - PMC - PubMed
    1. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998;32:S133‐S141. - PubMed
    1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038‐2047. - PubMed
    1. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62:849‐859. - PubMed
    1. Anaemia management in chronic kidney disease: clinical guideline: methods, evidence and recommendations. London: National Clinical Guidelines Centre; 2015. https://www.nice.org.uk/guidance/ng8 guidance/. Accessed June 3, 2015.

Publication types